Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Group 1 - Avadel Pharmaceuticals plc has granted non-statutory options to twelve new employees to purchase a total of 131,700 ordinary shares under its 2021 Inducement Plan [1] - The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of each employee's start date and 25% vesting on the second, third, and fourth anniversaries thereafter [1] - The grants were made as an inducement material to the employees' acceptance of employment in accordance with Nasdaq Listing Rule 5635(c)(4) [1] Group 2 - Avadel Pharmaceuticals is focused on transforming medicines to improve patients' lives, applying innovative solutions to medication development [2] - The company's commercial product, LUMRYZ™, is the first and only once-at-bedtime oxybate approved by the FDA for treating cataplexy or excessive daytime sleepiness in patients aged 7 years and older with narcolepsy [2]